FDA issues safety update guidance addendum
Summary bridging reports should be used to combine information presented in multiple periodic safety update reports, FDA says in 1addendum to the May 1997 guidance "E2C Clinical Safety Data Management: Periodic Safety Update Reports For Marketed Drugs." In addition, sponsors should use an addendum report to update a completed PSUR if the agency asks for safety data outside of the usual reporting cycle. The guidance was discussed during a March 2002 meeting (2"The Pink Sheet" March 18, 2002, p. 42)...
You may also be interested in...
The development of good vigilance practices will be the focus of both European Union and International Conference on Harmonization working groups
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.